News

A pooled analysis of three studies involving over 680 adults with type 2 diabetes showed that participants who added Exubera to their treatment regimen maintained glycemic control over

The phase II study was designed to evaluate whether inhaled insulin delivered through the Lilly/Alkermes system and injected insulin showed similar effectiveness at controlling blood sugar based on

The data indicates that the combination treatment provides longer event-free survival (EFS) in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) when compared to previous results with Rituxan

Clinical research conducted by the company in association with Oregon Health & Science University (OHSU) indicates that FOXP3, known to be involved in maintaining immune tolerance and regulation

The Global Alliance for TB Drug Development, also called the TB Alliance, was granted exclusive worldwide rights to PA-824 and related compounds by Chiron together with a commitment

The research and development company has also decided to initiate an expanded access program for TMC114, its investigational protease inhibitor, in the autumn of 2005 for people with

The vaccine is expected to enter phase II human trials in hematopoietic cell transplant (HCT) donor-recipients in the second half of 2005. The Orphan Drug Act is intended

Indiplon is a unique non-narcotic, non-benzodiazapine agent that acts on a specific site of the GABA-A receptor. Indiplon has been shown to bind selectively to the specific subtype

The US patent office has allowed GenoMed’s claims to use an existing drug for an alternative use. A full patent is anticipated to arrive in the near future,